MDT Medtronic Plc

Medtronic Announces Scientific Data Presentations at the American Diabetes Association 80th Scientific Sessions

Medtronic Announces Scientific Data Presentations at the American Diabetes Association 80th Scientific Sessions

Medtronic to Release New Data on Advanced Hybrid Closed-Loop Systems and Extended-Wear Infusion Set

DUBLIN, June 09, 2020 (GLOBE NEWSWIRE) --  (NYSE:MDT), the global leader in medical technology, today announced its participation at the American Diabetes Association 80th scientific sessions virtual meeting, June 12-16, 2020. Medtronic will be participating in this year’s ADA virtual sessions with 16 data presentations, a symposium, a product theater, and a virtual exhibit. Though its diverse ADA offerings, Medtronic will showcase the company’s automated insulin pump systems, continuous glucose monitoring (CGM) systems, and extended-wear infusion set technology; meaningful outcomes and differentiated support offerings, such as telehealth capabilities and the company response to the COVID-19 pandemic.

Virtual Exhibit

With the theme of “Innovation Beyond”, Medtronic will host a virtual exhibit booth featuring interactive components focused on diabetes technology, clinical outcomes, and support offerings for healthcare professionals and patients. The exhibit will showcase current product demonstrations, examples of real-world success with current diabetes technologies, and an overview of Medtronic telehealth support.

Key Events

The data from three trials using the next generation advanced hybrid closed loop system from Medtronic will be presented in a symposium. Medtronic will be participating in a product theater at this year’s conference. Details are as follows:

  •  chaired by Dr. Timothy S. Bailey on Friday, June 12, 2:00-4:00 p.m. CDT. Panelist and data to be presented will include:
Bruce W. Bode, M.D.U.S. Advanced Hybrid Closed-Loop (AHCL) Pivotal Safety Study
Richard M. Bergenstal, M.D.FLAIR—An NIDDK Sponsored International, Multi-Site Randomized Crossover Trial of AHCL vs. 670G
Martin de Bock, FRACP, Ph.D.New Zealand AHCL Randomized Crossover Trial (CE Mark Dataset)
  •  on Sunday, June 14, 3:00 – 3:45 p.m. CDT. Speakers to include:
Sean Salmon, president for the Diabetes Group at MedtronicWelcome & Overview
Amit Bhargava, M.D.The Next Generation of Guardian™ Connect CGM: Accuracy When it Matters Most with Real-World Outcomes
Jason Baker, M.D. & his patient, Sam Talbot, celebrity chef, author and entrepreneurVirtual Visit

Scientific Presentations 

The following 16 poster and oral scientific data presentations represent the work of Medtronic employees and independent investigators using Medtronic devices in their research:

Advanced Hybrid Closed Loop (AHCL)

  •  – poster presentation by Dr. Anders Carlson on Saturday, June 13 at 10:00 a.m. CDT.
  •  – poster presentation by Olivia Collyns and Dr. Martin de Bock on Saturday, June 13 at 10:00 a.m. CDT.
  •  – poster presentation by Dr. Amir Tirosh on Saturday, June 13 at 10:00 a.m. CDT.
  •  – poster presentation by Benyamin Grossman on Saturday, June 13 at 10:00 a.m. CDT.
  •  – poster presentation by David N. O’Neal on Saturday, June 13 at 10:00 a.m. CDT.
  •  – oral presentation by Dr. Martin de Bock on Sunday, June 14 at 3:15 p.m. CDT.
  •  – oral presentation by Dr. Melissa Lee and Dr. David O’Neal on Sunday, June 14 at 5:15 p.m. CDT.

Extended Wear Infusion Set

  •  – poster presentation by Jacob Ilany and Ohad Cohen on Saturday, June 13 at 10:00 a.m. CDT.
  •  – poster presentation by Sarnath Chattaraj on Saturday, June 13 at 10:00 a.m. CDT.
  • “ – poster presentation by Gina Zhang on Saturday, June 13 at 10:00 a.m. CDT.
  •  – poster presentation by Dr. Bruce Buckingham on Saturday, June 13 at 10:00 a.m. CDT.
  •  – poster presentation by Sarnath Chattaraj on Saturday, June 13 at 10:00 a.m. CDT.

Insulin Pump Therapy

  •  – poster presentation by Anirban Roy on Saturday, June 13 at 10:00 a.m. CDT.
  •  – poster presentation by Mona Shah on Saturday, June 13 at 10:00 a.m. CDT.

Multiple Daily Injections

  •  – poster presentation by Boyi Jiang on Saturday, June 13 at 10:00 a.m. CDT.

Continuous Glucose Monitoring (CGM)

  •  – poster presentation by Sinu Bessy Abraham on Saturday, June 13 at 10:00 a.m. CDT.

Analyst and Investor Briefing

Medtronic will host a webcast to highlight its Diabetes Group on Friday, June 12, from 5 p.m. to 6 p.m. CDT. The webcast will feature remarks from Medtronic management, including comments on Medtronic's clinical data, product pipelines, and market outlooks. The live audio webcast can be accessed by clicking on the Investor Events link at  on June 12. Within 24 hours of the webcast, a replay will be available on the same webpage. This event is not part of the official ADA Scientific Sessions.

About the Diabetes Group at Medtronic ()

Medtronic is working together with the global community to change the way people manage diabetes. The company aims to transform diabetes care by expanding access, integrating care and improving outcomes, so people living with diabetes can enjoy greater freedom and better health. 

About Medtronic

Medtronic plc (), headquartered in Dublin, Ireland, is among the world's largest medical technology, services and solutions companies - alleviating pain, restoring health and extending life for millions of people around the world. Medtronic employs more than 90,000 people worldwide, serving physicians, hospitals and patients in more than 150 countries. The company is focused on collaborating with stakeholders around the world to take healthcare Further, Together.

Any forward-looking statements are subject to risks and uncertainties such as those described in Medtronic's periodic reports on file with the Securities and Exchange Commission. Actual results may differ materially from anticipated results.

-end-





Kendra Cassillo

Public Relations

Ryan Weispfenning

Investor Relations

EN
09/06/2020

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Medtronic Plc

Research Team ACF
  • Research Team ACF

KDST + NLSP Combined Core Investment Case 29052025

We consider the merged platform Kadimastem (KDST.TA) + NLS Pharmaceutics (NLSP:NasdaqCM). We provide an investment case analysis and a selection of merged metrics prior to any synergies. The merger creates a cross-platform pre-revenue biotech with lead programs including a proprietary stem-differentiation platform capable of delivering scalable therapies for replacing lost or damaged cells; IsletRx could revolutionize insulin production for Type 1 diabetes (T1D) patients; AstroRx® targets neurod...

Research Team ACF
  • Research Team ACF

ACF Thematic Research Regenerative Medicine Diabetes Treatment & Innov...

Diabetes mellitus, Type 1 (T1D) and Type 2 (T2D, 85-90% of cases), is a USD ~75bn global therapy market. Global economic costs of diabetes may exceed USD1 trn today and USD 450bn in the US, suggesting a pressing global health challenge. Diabetes is a chronic metabolic disorder characterized by high blood sugar levels. In 2024, consensus global estimates suggested there were ~800m adult diabetes sufferers. In 2021, according to the IDF there >530m sufferers globally. For 2027E we modestly forecas...

Dave Nicoski ... (+2)
  • Dave Nicoski
  • Ross LaDuke

Vermilion Compass: Weekly Equity Strategy

S&P 500 Holding Above Prior Breakout Level Yet Again As discussed throughout the first half of January, we continue to believe that tariffs will mostly be used as a negotiation tactic, and much like Trump's prior presidency, will be much less impactful than feared. We reiterated this in yesterday's pre-market ETF Pathfinder, also noting "we anticipate the Canada/Mexico tariffs to be resolved relatively quickly, and therefore we view the latest pullback as a buying opportunity." Sure enough, bot...

Dave Nicoski ... (+2)
  • Dave Nicoski
  • Ross LaDuke

Vermilion Compass: Weekly Equity Strategy

S&P 500 Testing Prior Breakout Level DeepSeek appears to have turned the chatbot market upside-down, putting pressure on AI-linked stocks. While the dust has yet to settle, the good news is that the selloff has been largely contained to these AI-linked stocks. The rest of the market did not seem to care; the equal-weighted S&P 500 was roughly flat yesterday. Additionally, market dynamics remain healthy, with Treasury yields, the U.S. dollar (DXY), and WTI crude oil continuing to move lower, and...

Medtronic, Inc.: Update to credit analysis

Our credit view of this issuer reflects its strong product diversification, offset by its large payouts to shareholders.

ResearchPool Subscriptions

Get the most out of your insights

Get in touch